FENNEC (FENC) CFO Andrade gains 1,703 vested shares, now holds 290,972

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Financial Officer Robert Andrade reported a compensation-related share event. He acquired 1,703 common shares at a price of $0.00 per share through a grant/award acquisition, representing shares released from restrictions on prior awards. Following this release, he directly holds 290,972 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Andrade Robert

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Common shares	1,703	$0.00	--

Holdings After Transaction: Common shares — 290,972 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 1,703 shares Transaction price: $0.00 per share Post-transaction holdings: 290,972 shares +1 more

4 metrics

Shares acquired 1,703 shares Grant/award acquisition of common shares

Transaction price $0.00 per share Price for grant/award acquisition

Post-transaction holdings 290,972 shares Common shares directly held after transaction

Award grant dates May 16, 2024 and March 28, 2025 Original dates of restricted share awards

Key Terms

grant/award acquisition, restricted shares, Form 4, chief financial officer

4 terms

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

restricted shares financial

"Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025."

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

chief financial officer financial

"officer_title": "CHIEF FINANCIAL OFFICER""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:35 PM Accepted by SEC EDGAR 07/01/2026 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrade Robert

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	06/30/2026		A		1,703	A	$0	290,972	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025.

	/s/ Robert Andrade	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did FENNEC (FENC) report for CFO Robert Andrade?

FENNEC reported that CFO Robert Andrade acquired 1,703 common shares through a grant/award acquisition. These shares were released from restrictions tied to awards granted on May 16, 2024 and March 28, 2025, reflecting routine equity compensation vesting.

Was the FENNEC (FENC) CFO share transaction a market purchase or sale?

The transaction was not a market purchase or sale. Andrade received 1,703 common shares at $0.00 per share as part of a grant/award acquisition, representing restricted shares that became unrestricted rather than shares bought or sold on the open market.

How many FENNEC (FENC) shares does the CFO hold after this Form 4?

After the reported transaction, CFO Robert Andrade directly holds 290,972 common shares. The filing shows this total reflects his position following the release of 1,703 previously restricted shares from earlier equity awards, giving investors updated visibility into his direct ownership stake.

What is the significance of the 1,703 FENNEC (FENC) shares released from restriction?

The 1,703 shares represent equity compensation that vested from awards dated May 16, 2024 and March 28, 2025. This is a standard compensation event, with shares becoming freely owned by the CFO, rather than a discretionary trade based on his view of the stock’s value.

Did the FENNEC (FENC) CFO pay anything for the 1,703 shares acquired?

No cash was paid for these shares. The Form 4 lists a transaction price of $0.00 per share, indicating the 1,703 common shares were delivered as part of a compensation grant/award, linked to the release of restrictions on prior equity awards granted in 2024 and 2025.